PARIS–(BUSINESS WIRE)–HighLife SAS, a medtech company focused on the development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, announced today the appointment of Mr. Jose (“Pepe”) Calle Gordo as Chairman of its Board of Directors. Pepe brings 30 years of broad business and management experience in the […]
Other News
Janssen Submits Supplemental NDA to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients With Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
RARITAN, N.J., Dec. 11, 2017 /PRNewswire/ — Janssen Research & Development today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new XARELTO® (rivaroxaban) vascular indications: reducing the risk of major cardiovascular (CV) events such as CV death, heart attack or stroke […]
Imricor Awarded NIH Contract to Develop MR Compatible Catheter for MRI-Guided Cardiac Procedures
Minneapolis, MN – December 5, 2017 – Imricor Medical Systems announced that it has been awarded a contract for up to $2.4 million from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) to develop an MR compatible injection catheter for MRI-guided procedures. This ten month […]
The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial; MiStent Achieved Primary Endpoint vs Xience®
DURHAM, N.C., Dec. 6, 2017 /PRNewswire/ — Micell Technologies, Inc. announced that The Lancet has published data from the DESSOLVE III clinical trial. The study met its primary endpoint, showing non-inferior safety and effectiveness outcomes in a complex patient population for the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) versus the Xience® Everolimus Eluting […]
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
NEW YORK, Dec. 7, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance during its annual investor conference today […]
Edwards Lifescience Scoops Up Harpoon Medical for $100M
IRVINE, Calif., Dec. 6, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the acquisition of Harpoon Medical, a privately held medical technology company pioneering beating-heart repair for degenerative mitral regurgitation (DMR). Edwards announced a structured upfront investment […]
PVD Patients Boomeranging at Higher Rates After Intervention, Study Shows
By Ken Dropiewski, Prime-Core Executive Search (ken@prime-core.com) As we progress to value-based healthcare system, it’s more important than ever to keep readmissions to a minimum. A recent study, though, found that more than 17 percent of patients undergoing peripheral revascularization for PVD were readmitted within 30 days of having the procedure.The unplanned […]
Robocath raises a total of €6.4 million ($7.6M) in 2017
Robocath receives an additional €1.25 million financial contribution from Crédit Agricole Innovations et Territoires (CAIT), an innovation fund managed by Supernova Invest. In line with the company’s growth strategy, the new funding aims to increase the resources available to market the R-OneTM product and launch the development of the next generation of […]
4C Medical’s Novel Transcatheter Mitral Valve Technology Awarded Best Technology Parade Presentation at ICI 2017
BROOKLYN PARK, Minn., Dec. 5, 2017 /PRNewswire/ — 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its medical device for mitral regurgitation (MR) was awarded the Best Technology Parade Presentation at the International Conference for Innovations in Cardiovascular Interventions (ICI) held December 3-5, […]
Neovasc Reducer Featured in Live Case at ICI 2017
VANCOUVER, Dec. 6, 2017 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ, TSX: NVCN) today reported its Neovasc Reducer™ (“Reducer”) medical device was featured in a “live case” broadcast at the 2017 Innovations in Cardiovascular Interventions (ICI) conference held in Tel Aviv, Israel. In the live case broadcast to the conference from […]



